(Q36790314)

16 August 2017

1 reference

title

Chronic administration of ketamine for analgesia (English)

1 reference

16 August 2017

Alon Ben-Ari

1

1 reference

PubMed ID

17430824

16 August 2017

Michael C Lewis

series ordinal

2

1 reference

PubMed ID

17430824

16 August 2017

Elyad Davidson

series ordinal

3

1 reference

16 August 2017

1 January 2007

1 reference

Journal of Pain and Palliative Care Pharmacotherapy

16 August 2017

1 reference

16 August 2017

21

1 reference

16 August 2017

1

1 reference

16 August 2017

7-14

1 reference

PHARMACOLOGIC EFFECTS OF CI-581, A NEW DISSOCIATIVE ANESTHETIC, IN MAN.

16 August 2017

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Comparative pharmacology of the ketamine isomers. Studies in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Double-blind randomized controlled trial of caudal versus intravenous S(+)-ketamine for supplementation of caudal analgesia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Iontophoretic administration of S(+)-ketamine in patients with intractable central pain: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Ketamine analgesia is not related to an opiate action in the periaqueductal gray region of the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

The induction and maintenance of central sensitization is dependent on N -methyl-d-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Analgesic effect of oral ketamine in chronic neuropathic pain of spinal origin: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Treatment of central post-stroke pain with oral ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Peripheral excitatory amino acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Intraplantar injection of dextrorphan, ketamine or memantine attenuates formalin-induced behaviors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Peripheral analgesic effects of ketamine in acute inflammatory pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Topical ketamine gel: possible role in treating neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Immediate and long-term phantom limb pain in amputees: incidence, clinical characteristics and relationship to pre-amputation limb pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Oral ketamine therapy in the treatment of postamputation stump pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Intrathecal S(+)-ketamine in refractory neuropathic cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

"Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Long-term intrathecal S(+)-ketamine in a patient with cancer-related neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for the management of neuropathic cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Tolerance to rectal ketamine in paediatric anaesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Clinical experience with oral ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Patterns of use and harms associated with non-medical ketamine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Ketamine impairs multiple cognitive domains in rhesus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ354V21N01_04

21 January 2018

Identifiers

DOI

10.1080/J354V21N01_04

1 reference

16 August 2017

1 reference

PubMed ID

17430824